LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

2.76 2.22

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.67

Максимум

2.83

Ключови измерители
By Trading Economics
Приходи	4.1M -5.7M
Служители	34
EBITDA	3.1M -6.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+638.01% upside

Дивиденти
By Dow Jones
Следващи печалби	2.06.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-139M 250M
Предишно отваряне	0.54
Предишно затваряне	2.76

Настроения в новините

By Acuity

67%

33%

290 / 344 Класиране в Healthcare

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.05.2026 г., 21:33 ч. UTC

Печалби

Correction to Salesforce 1Q Sales, Profit Rise Article

27.05.2026 г., 21:00 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare Agrees to Buy The College of Health Care Professions

27.05.2026 г., 20:18 ч. UTC

Печалби

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27.05.2026 г., 23:49 ч. UTC

Пазарно говорене

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

27.05.2026 г., 23:08 ч. UTC

Пазарно говорене

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27.05.2026 г., 22:21 ч. UTC

Пазарно говорене

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27.05.2026 г., 21:29 ч. UTC

Горещи акции

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27.05.2026 г., 21:08 ч. UTC

Печалби

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27.05.2026 г., 21:02 ч. UTC

Печалби

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27.05.2026 г., 20:59 ч. UTC

Придобивния, сливания и поглъщания

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27.05.2026 г., 20:55 ч. UTC

Печалби

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

27.05.2026 г., 20:48 ч. UTC

Печалби

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27.05.2026 г., 20:45 ч. UTC

Печалби

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27.05.2026 г., 20:34 ч. UTC

Придобивния, сливания и поглъщания

Webster Financial Stockholders Approve Sale to Banco Santander

27.05.2026 г., 20:32 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27.05.2026 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27.05.2026 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27.05.2026 г., 20:30 ч. UTC

Печалби

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27.05.2026 г., 20:30 ч. UTC

Придобивния, сливания и поглъщания

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27.05.2026 г., 20:22 ч. UTC

Печалби

Salesforce Stock Slides on Mixed Results -- Barrons.com

27.05.2026 г., 20:16 ч. UTC

Печалби

Salesforce Stock Slides on Mixed Results -- Barrons.com

27.05.2026 г., 20:13 ч. UTC

Печалби

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27.05.2026 г., 20:13 ч. UTC

Печалби

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27.05.2026 г., 20:13 ч. UTC

Печалби

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27.05.2026 г., 20:12 ч. UTC

Печалби

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27.05.2026 г., 20:12 ч. UTC

Печалби

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

638.01% нагоре

12-месечна прогноза

Среден 20 USD 638.01%

Висок 20 USD

Нисък 20 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Настроение

By Acuity

290 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.